Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab (SUSTAIN)

25 september 2019 bijgewerkt door: Biogen

A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab (SUSTAIN)

The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) participants, who switched from treatment with natalizumab to daclizumab due to safety concerns. The secondary objectives of this study in this study population are to evaluate the effects of daclizumab on the following: 1) Multiple Sclerosis (MS) relapse activity including the annualized relapse rate (ARR) and the proportion of participants experiencing relapses requiring hospitalization and/or steroid treatment; 2) MS-related outcomes measured using magnetic resonance imaging (MRI); 3) Safety and tolerability in participants previously treated with natalizumab.

Studie Overzicht

Toestand

Beëindigd

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Werkelijk)

41

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Canada
    • Alberta
      • Edmonton, Alberta, Canada, T6G 2G3
        • Research Site
  • Duitsland
      • Hamburg, Duitsland, 20249
        • Research Site
    • Bayern
      • Muenchen, Bayern, Duitsland, 81675
        • Research Site
    • Brandenburg
      • Potsdam, Brandenburg, Duitsland, 14471
        • Research Site
    • Sachsen
      • Dresden, Sachsen, Duitsland, 01307
        • Research Site
  • Italië
      • Napoli, Italië, 80131
        • Research Site
    • Isernia
      • Pozzilli, Isernia, Italië, 86077
        • Research Site
  • Puerto Rico
      • Guaynabo, Puerto Rico, 00968
        • Research Site
  • Verenigde Staten
    • Florida
      • Tampa, Florida, Verenigde Staten, 33612
        • Research Site
    • Iowa
      • Des Moines, Iowa, Verenigde Staten, 50314
        • Research Site
    • Wisconsin
      • Milwaukee, Wisconsin, Verenigde Staten, 53501
        • Research Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 55 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Key Inclusion Criteria

  • Must have documented diagnosis of RRMS (McDonald 2010 Criteria) at screening [Polman 2011].
  • Must have been treated with natalizumab for at least the 12 months prior to screening and have not missed 2 or more consecutive scheduled doses.
  • Must be naïve to daclizumab and other forms of daclizumab such as Zenapax® prior to enrollment.
  • Must have a confirmed Expanded Disability Status Scale (EDSS) score of 0 to 5.5, inclusive, at screening.
  • Female participants of childbearing potential must practice effective contraception from Day -1 and be willing and able to continue contraception for duration of the study.

Key Exclusion Criteria

  • Current participation in another investigational study.
  • Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold) [Lublin 2014].
  • Females breastfeeding, pregnant, or planning to become pregnant; or women who have a positive pregnancy test result during screening.
  • History of drug or alcohol abuse (as defined by the Investigator) within 1 year prior to screening.
  • History of severe hypersensitivity (e.g., anaphylaxis or anaphylactoid reactions) to the active ingredient or any of the excipients.
  • History of severe opportunistic infections (including progressive multifocal leukoencephalopathy (PML)) or any clinically significant, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic (other than MS), dermatologic, psychiatric, and renal, or other major disease, as determined by the Investigator.
  • Discontinued natalizumab due to suspicion of PML.
  • Known active malignancies (participants with cutaneous basal cell carcinoma that has been completely excised prior to study entry remain eligible).
  • The participant is using another MS therapy concomitantly.
  • Known history of human immunodeficiency virus (HIV).
  • Positive test result for Hepatitis C virus (test for hepatitis C virus antibody [HCV Ab]) or hepatitis B virus (test for hepatitis B surface antigen [HBsAg] and/or hepatitis B core antibody [HBcAb]).
  • The participant has been treated with immunosuppressive or immunomodulating treatments including mitoxantrone, azathioprine, methotrexate, cyclophosphamide, or mycophenolate mofetil.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Daclizumab
Geneesmiddel: Daclizumab
High yield formulation
Andere namen:
  • Zinbryta
  • BIIB019

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants Relapse-free at Month 6
Tijdsspanne: Month 6
Relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Examining Neurologist. The Kaplan-Meier estimate of the percentage of participants relapse-free at Month 6 is reported.
Month 6

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants Relapse-free at Month 12
Tijdsspanne: Month 12
Relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Examining Neurologist.
Month 12
Percentage of Participants Experiencing Relapse Requiring Hospitalization and/or Steroid Treatment at Month 12
Tijdsspanne: Month 12
Relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Examining Neurologist.
Month 12
Annualized Relapse Rate (ARR) at Month 12
Tijdsspanne: Month 12
Relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Examining Neurologist. The ARR was calculated by tabulating the total number of relapses experienced in the group divided by the number of days up to the end of Month 12, and the ratio then multiplied by 365.
Month 12
Number of Participants With New Gadolinium-Enhanced (Gd+) and T1 Hypointense Lesions at Months 6 and 12
Tijdsspanne: Months 6 and 12
New Gadolinium-Enhanced (Gd+) and T1 Hypointense Lesions were assessed using magnetic resonance imaging (MRI).
Months 6 and 12
Number of Participants With New and Newly Enlarged T2 Hypointense Lesions at Months 6 and 12
Tijdsspanne: Months 6 and 12
New and newly enlarged T2 Hypointense Lesions were measured by MRI.
Months 6 and 12
Permanent Discontinuation Rate of Daclizumab at Month 12
Tijdsspanne: Month 12
Permanent Discontinuation Rate was calculated as the ratio of number of participants who had permanently discontinued daclizumab prior to Month 12 over the total number of participants who received at least 1 dose of daclizumab in the study.
Month 12
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tijdsspanne: First dose of study drug to within 30 days of last dose (up to 11 months)
An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death or in the view of the Investigator, places the participant at immediate risk of death or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability or results in a birth defect.
First dose of study drug to within 30 days of last dose (up to 11 months)
Number of Participants With Clinically Relevant Shifts in Laboratory Assessments
Tijdsspanne: First dose of study drug to within 30 days of last dose (up to 11 months)
Clinical Laboratory assessments were tests of Chemistry and Hematology. The investigator determined if any of the laboratory results were clinically relevant shifts from Baseline.
First dose of study drug to within 30 days of last dose (up to 11 months)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Biogen

Medewerkers

AbbVie

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

18 april 2017

Primaire voltooiing (Werkelijk)

12 september 2018

Studie voltooiing (Werkelijk)

12 september 2018

Studieregistratiedata

Eerst ingediend

24 augustus 2016

Eerst ingediend dat voldeed aan de QC-criteria

26 augustus 2016

Eerst geplaatst (Schatting)

29 augustus 2016

Updates van studierecords

Laatste update geplaatst (Werkelijk)

27 september 2019

Laatste update ingediend die voldeed aan QC-criteria

25 september 2019

Laatst geverifieerd

1 september 2019

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 205MS305
  • 2016-002820-10 (EudraCT-nummer)

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren